Dr. David Sugarbaker - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned refs (RON-2026-04-05-003)

2026-04-06T10:12:40Z

Fix structural reference errors: remove orphaned refs (RON-2026-04-05-003)

← Older revision		Revision as of 10:12, 6 April 2026
Line 355:		Line 355:
	<ref name="nci_surgery">[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>		<ref name="nci_surgery">[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>
	<ref name="dandell_meso">[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref>		<ref name="dandell_meso">[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref>
	<ref name="pubmed_9869758">[https://pubmed.ncbi.nlm.nih.gov/9869758/ Sugarbaker DJ et al. "Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients." J Thorac Cardiovasc Surg. 1999;117(1):54-63], PubMed</ref>
	<ref name="brigham_imp">[https://www.brighamandwomens.org/lung-center/chest-and-lung-cancer-programs/international-mesothelioma-program-overview International Mesothelioma Program Overview], Brigham and Women's Hospital</ref>		<ref name="brigham_imp">[https://www.brighamandwomens.org/lung-center/chest-and-lung-cancer-programs/international-mesothelioma-program-overview International Mesothelioma Program Overview], Brigham and Women's Hospital</ref>
	<ref name="va_asbestos">[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>		<ref name="va_asbestos">[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>
Line 368:		Line 367:
	<ref name="mesonet_prognosis">[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref>		<ref name="mesonet_prognosis">[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Prognosis], Mesothelioma.net</ref>
	<ref name="mesonet_emerging_treatments">[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>		<ref name="mesonet_emerging_treatments">[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
	<ref name="pubmed_15559059">[https://pubmed.ncbi.nlm.nih.gov/15559059/ Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications. Thorac Surg Clin. 2004;14(4):523-528], PubMed</ref>
	<ref name="dandell_case_worth">[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>		<ref name="dandell_case_worth">[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>
	<ref name="pubmed_23434448">Sugarbaker DJ et al. "Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection." J Thorac Cardiovasc Surg. 2013;145(4):955-963. [https://pubmed.ncbi.nlm.nih.gov/23434448/ PubMed]</ref>		<ref name="pubmed_23434448">Sugarbaker DJ et al. "Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection." J Thorac Cardiovasc Surg. 2013;145(4):955-963. [https://pubmed.ncbi.nlm.nih.gov/23434448/ PubMed]</ref>

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-09T04:00:12Z

Add differentiated triple GEO format

Show changes

MesotheliomaSupport: Fix factual errors: born date (Aug 5, 1953 not Aug 6, 1949), age at death (65 not 69), survival figure (35.3 not 35.6 months), correct HIPEC PMID (23434448 not 9869758), add obituary ref PMC6379011, soften unverifiable surgical volume claim

2026-03-07T03:31:22Z

Fix factual errors: born date (Aug 5, 1953 not Aug 6, 1949), age at death (65 not 69), survival figure (35.3 not 35.6 months), correct HIPEC PMID (23434448 not 9869758), add obituary ref PMC6379011, soften unverifiable surgical volume claim

Show changes

MesotheliomaSupport: Internal linking: added 2 wiki links

2026-02-20T20:57:08Z

Internal linking: added 2 wiki links

← Older revision		Revision as of 20:57, 20 February 2026
Line 36:		Line 36:
	== Executive Summary ==		== Executive Summary ==

	Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+dj+mesothelioma PubMed: Sugarbaker DJ Mesothelioma], National Library of Medicine</ref>		Dr. David J. Sugarbaker stands among the most influential [[Mesothelioma\|mesothelioma]] surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+dj+mesothelioma PubMed: Sugarbaker DJ Mesothelioma], National Library of Medicine</ref>

	The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, [[Clinical Trials\|clinical trials]], and training programs that advanced the field worldwide.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>		The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, [[Clinical Trials\|clinical trials]], and training programs that advanced the field worldwide.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>
Line 175:		Line 175:

	* '''Tissue Banking:''' Established protocols that enabled genomic research		* '''Tissue Banking:''' Established protocols that enabled genomic research
	* '''Clinical Trials:''' Tested innovative therapeutic combinations		* '''[[Clinical Trials]]:''' Tested innovative therapeutic combinations
	* '''Staging Systems:''' Developed the Brigham staging system for surgical planning		* '''Staging Systems:''' Developed the Brigham staging system for surgical planning
	* '''Molecular Tools:''' Created the four-gene ratio test for personalized medicine		* '''Molecular Tools:''' Created the four-gene ratio test for personalized medicine

MesotheliomaSupport: Internal linking: added 4 wiki links

2026-02-20T20:54:11Z

Internal linking: added 4 wiki links

MesotheliomaSupport: Fix Brigham and Women's Hospital link encoding (%27 to apostrophe)

2026-02-20T01:36:42Z

Fix Brigham and Women's Hospital link encoding (%27 to apostrophe)

← Older revision		Revision as of 01:36, 20 February 2026
Line 249:		Line 249:
	* [[Dr_Robert_Cameron\|Dr. Robert Cameron]]		* [[Dr_Robert_Cameron\|Dr. Robert Cameron]]
	* [[Dr_Paul_Baas\|Dr. Paul Baas]]		* [[Dr_Paul_Baas\|Dr. Paul Baas]]
	* [[~~Brigham_and_Women%27s_Hospital~~\|Brigham and Women's Hospital]]		* [[Brigham and Women's Hospital\|Brigham and Women's Hospital]]
	* [[Treatment_Options\|Treatment Options]]		* [[Treatment_Options\|Treatment Options]]
	* [[Mesothelioma_Treatment_Centers\|Mesothelioma Treatment Centers]]		* [[Mesothelioma_Treatment_Centers\|Mesothelioma Treatment Centers]]

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:28:53Z

Fix dark mode compatibility: remove problematic background/text colors

MesotheliomaSupport: Fix dark mode styling

2026-01-29T03:00:38Z

Fix dark mode styling

New page

{{#seo:
|title=Dr. David Sugarbaker: Pioneer of Mesothelioma Surgery and Trimodal Therapy
|description=Dr. David Sugarbaker pioneered extrapleural pneumonectomy and trimodal therapy, founded the International Mesothelioma Program, and performed more mesothelioma surgeries than any other surgeon.
|keywords=Dr. David Sugarbaker, extrapleural pneumonectomy, trimodal therapy, International Mesothelioma Program, Brigham and Women's Hospital, mesothelioma surgery
|image=dr-david-sugarbaker-mesothelioma-surgeon.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-01-28
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; color:#333333; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Dr. David J. Sugarbaker, MD
|-
| colspan="2" style="background:#e8f4f8; color:#333333; padding:10px; text-align:center; font-style:italic;" | Architect of Trimodal Therapy
|-
| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Born
| style="padding:10px; border-bottom:1px solid #dee2e6;" | August 6, 1949
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Died
| style="padding:10px; border-bottom:1px solid #dee2e6;" | August 29, 2018 (age 69)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Institution
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Brigham and Women's Hospital
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Key Innovation
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Trimodal Therapy
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" | Program Founded
| style="padding:10px; border-bottom:1px solid #dee2e6;" | International Mesothelioma Program (2002)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333;" | Survival Achievement
| style="padding:10px;" | 35.6 months median
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
|}

== Executive Summary ==

Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+dj+mesothelioma PubMed: Sugarbaker DJ Mesothelioma], National Library of Medicine</ref>

The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, clinical trials, and training programs that advanced the field worldwide.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>

Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Dr. David Sugarbaker's Contributions
|-
| style="padding:15px; background:#f8f9fa; color:#333333;" |
* '''Surgical Innovation:''' Pioneered extrapleural pneumonectomy (EPP) for mesothelioma
* '''Trimodal Therapy:''' Developed approach combining surgery + chemotherapy + radiation
* '''Survival Achievement:''' 35.6 months median survival with trimodal therapy + HIPEC
* '''Program Founded:''' International Mesothelioma Program at Brigham and Women's Hospital (2002)
* '''Collaborating Institutions:''' Brigham and Women's, Dana-Farber, MGH, Boston VA, Harvard School of Public Health
* '''Brigham Staging System:''' Created staging system identifying surgical candidates
* '''Four-Gene Ratio Test:''' Developed molecular tool for personalized treatment decisions
* '''Surgical Volume:''' Performed more mesothelioma surgeries than any other surgeon in history
* '''Training Legacy:''' Trained numerous thoracic surgeons who continue his methods
* '''Research Output:''' Extensive body of publications establishing surgical treatment standards
|}

== Who Was Dr. David Sugarbaker and Why Is He Considered a Pioneer? ==

Dr. David J. Sugarbaker (August 6, 1949 – August 29, 2018) was a thoracic surgeon who dedicated his career to developing surgical treatments for mesothelioma patients who previously had few options.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> Based at Brigham and Women's Hospital in Boston, Sugarbaker transformed the surgical treatment of this asbestos-related cancer from a largely futile endeavor into a viable therapeutic option for carefully selected patients.

His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER Program</ref>

{| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}

== What Was Extrapleural Pneumonectomy and How Did Dr. Sugarbaker Improve It? ==

Extrapleural pneumonectomy (EPP) is an aggressive surgical procedure that removes the affected lung, the pleura (lining around the lung), the pericardium (lining around the heart), and the diaphragm.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/extrapleural-pneumonectomy Extrapleural Pneumonectomy], NCI Dictionary of Cancer Terms</ref> The goal is to remove as much cancer as possible, achieving what surgeons call "complete macroscopic resection."

While EPP existed before Sugarbaker, he significantly refined the procedure. In 1992, the Annals of Thoracic Surgery published his research on overcoming the technical difficulties of EPP through improved operative techniques.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+extrapleural+pneumonectomy PubMed: Sugarbaker EPP Studies], National Library of Medicine</ref> His modifications included:

* '''Improved Patient Selection:''' Developing criteria to identify patients most likely to benefit
* '''Refined Surgical Technique:''' Reducing operative mortality and complications
* '''Reconstruction Methods:''' Better approaches to rebuilding the diaphragm and pericardium
* '''Perioperative Care:''' Protocols to optimize patient outcomes before and after surgery

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Structure Removed
! style="background:#1a5276; color:white; padding:10px;" | Rationale
|-
| style="padding:10px;" | Affected Lung
| style="padding:10px;" | Mesothelioma typically encases the lung
|-
| style="padding:10px;" | Parietal Pleura
| style="padding:10px;" | Primary site of mesothelioma origin
|-
| style="padding:10px;" | Visceral Pleura
| style="padding:10px;" | Disease spreads along pleural surfaces
|-
| style="padding:10px;" | Pericardium
| style="padding:10px;" | Often involved with advanced disease
|-
| style="padding:10px;" | Hemidiaphragm
| style="padding:10px;" | Frequently invaded by tumor
|}

{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.
|}

== What Is Trimodal Therapy and Why Did Dr. Sugarbaker Develop It? ==

Sugarbaker's most significant contribution was developing trimodal therapy—the combination of surgery, chemotherapy, and radiation therapy to maximize survival in patients with operable mesothelioma.<ref>[https://www.cancer.gov/about-cancer/treatment/types Treating Cancer], National Cancer Institute</ref>

=== The Trimodal Approach ===

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Component
! style="background:#1a5276; color:white; padding:10px;" | Timing
! style="background:#1a5276; color:white; padding:10px;" | Purpose
|-
| style="padding:10px;" | '''Chemotherapy'''
| style="padding:10px;" | Before and/or after surgery
| style="padding:10px;" | Shrink tumor, kill microscopic disease
|-
| style="padding:10px;" | '''Surgery (EPP)'''
| style="padding:10px;" | Central component
| style="padding:10px;" | Remove all visible disease
|-
| style="padding:10px;" | '''Radiation'''
| style="padding:10px;" | After surgery
| style="padding:10px;" | Destroy remaining cancer cells
|}

Sugarbaker's research demonstrated that combining these treatments achieved better results than any single modality alone. His studies showed that patients receiving intraoperative chemotherapy lived over one year longer than those who did not.<ref>[https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy Radiation Therapy to Treat Cancer], National Cancer Institute</ref>

=== HIPEC Integration ===

In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.6 months, with half of patients living even longer.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✅ Survival Achievement:''' Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.6 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.
|}

== What Was the International Mesothelioma Program? ==

In 2002, Sugarbaker founded the International Mesothelioma Program (IMP) at Brigham and Women's Hospital, creating the world's largest mesothelioma research and treatment initiative.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center International Mesothelioma Program], Brigham and Women's Hospital</ref>

=== Collaborating Institutions ===

The IMP brought together specialists from five Boston-area institutions:

* '''Brigham and Women's Hospital''' – Surgical treatment and inpatient care
* '''Dana-Farber Cancer Institute''' – Medical oncology and chemotherapy
* '''Massachusetts General Hospital''' – Radiation oncology
* '''Boston VA Health Care System''' – Veteran care
* '''Harvard School of Public Health''' – Epidemiology and research

This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>

{| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}

=== IMP Contributions ===

Under Sugarbaker's leadership, the IMP produced numerous advances:<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&term=brigham Brigham Mesothelioma Trials], ClinicalTrials.gov</ref>

* '''Tissue Banking:''' Established protocols that enabled genomic research
* '''Clinical Trials:''' Tested innovative therapeutic combinations
* '''Staging Systems:''' Developed the Brigham staging system for surgical planning
* '''Molecular Tools:''' Created the four-gene ratio test for personalized medicine
* '''Training Programs:''' Educated thoracic surgeons who spread these techniques worldwide

== What Was the Brigham Staging System? ==

Dr. Sugarbaker developed the Brigham staging system to identify which patients were appropriate candidates for aggressive surgical intervention.<ref>[https://www.cancer.gov/about-cancer/diagnosis-staging/staging Staging], National Cancer Institute</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Stage
! style="background:#1a5276; color:white; padding:10px;" | Disease Extent
! style="background:#1a5276; color:white; padding:10px;" | Surgery Appropriate?
|-
| style="padding:10px;" | '''Stage I'''
| style="padding:10px;" | Disease confined to pleura
| style="padding:10px;" | '''Yes''' – Resectable
|-
| style="padding:10px;" | '''Stage II'''
| style="padding:10px;" | Resectable with positive lymph nodes
| style="padding:10px;" | '''Yes''' – Resectable
|-
| style="padding:10px;" | '''Stage III'''
| style="padding:10px;" | Extended locally but technically resectable
| style="padding:10px;" | Selected cases only
|-
| style="padding:10px;" | '''Stage IV'''
| style="padding:10px;" | Distant metastases or unresectable
| style="padding:10px;" | '''No''' – Not candidates for EPP
|}

This staging system specifically addressed the question of surgical resectability—helping surgeons determine which patients could benefit from aggressive surgery and which should receive non-surgical treatment.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER</ref>

== What Is Dr. Sugarbaker's Legacy? ==

Dr. David Sugarbaker died on August 29, 2018, having transformed mesothelioma treatment from a largely hopeless endeavor into a field where survival could be measured in years rather than months for selected patients.<ref>[https://www.osha.gov/asbestos Asbestos], Occupational Safety and Health Administration</ref>

=== Immediate Legacy ===

* '''Surgical Volume:''' Performed more mesothelioma surgeries than any other surgeon in history
* '''Training:''' Educated thoracic surgeons who continue his methods at institutions worldwide
* '''Research:''' Published extensively, creating the evidence base for surgical treatment
* '''Institution Building:''' The IMP continues operating under [[Dr_Raphael_Bueno|Dr. Raphael Bueno's]] leadership

=== Lasting Impact ===

* '''Multimodal Therapy:''' The principle of combining treatments remains standard practice
* '''Personalized Medicine:''' Molecular testing to guide treatment decisions is now routine
* '''Surgical Selection:''' Careful patient selection based on staging continues to guide practice
* '''Research Infrastructure:''' Tissue banks and databases support ongoing research

{| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Client Advocate, Danziger & De Llano
|}

== Get Help Today ==

If you or a loved one has been diagnosed with mesothelioma, accessing the best possible treatment—including the surgical techniques Dr. Sugarbaker pioneered—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 '''Call (866) 222-9990''' or [https://dandell.com/contact-us/ request a free case review online].

== See Also ==

* [[History_of_Mesothelioma_Research|History of Mesothelioma Research]]
* [[Dr_Raphael_Bueno|Dr. Raphael Bueno]] (Successor at IMP)
* [[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]] (Peritoneal Mesothelioma Pioneer)
* [[Dr_Robert_Cameron|Dr. Robert Cameron]]
* [[Dr_Paul_Baas|Dr. Paul Baas]]
* [[Brigham_and_Women%27s_Hospital|Brigham and Women's Hospital]]
* [[Treatment_Options|Treatment Options]]
* [[Mesothelioma_Treatment_Centers|Mesothelioma Treatment Centers]]

== References ==

<references />

[[Category:Mesothelioma Research]]
[[Category:Mesothelioma Researchers]]
[[Category:Mesothelioma]]
[[Category:Treatment History]]

← Older revision		Revision as of 20:54, 20 February 2026
Line 26:		Line 26:
	\|-		\|-
	\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Program Founded		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Program Founded
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International Mesothelioma Program (2002)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International [[Mesothelioma]] Program (2002)
	\|-		\|-
	\| style="padding:10px; font-weight:bold; " \| Survival Achievement		\| style="padding:10px; font-weight:bold; " \| Survival Achievement
Line 38:		Line 38:
	Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+dj+mesothelioma PubMed: Sugarbaker DJ Mesothelioma], National Library of Medicine</ref>		Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center Mesothelioma Treatment Center], Brigham and Women's Hospital</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=sugarbaker+dj+mesothelioma PubMed: Sugarbaker DJ Mesothelioma], National Library of Medicine</ref>

	The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, clinical trials, and training programs that advanced the field worldwide.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>		The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, [[Clinical Trials\|clinical trials]], and training programs that advanced the field worldwide.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref>

	Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>		Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>
Line 236:		Line 236:
	== Get Help Today ==		== Get Help Today ==

	If you or a loved one has been diagnosed with mesothelioma, accessing the best possible treatment—including the surgical techniques Dr. Sugarbaker pioneered—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>		If you or a loved one has been diagnosed with mesothelioma, accessing the best possible treatment—including the surgical techniques Dr. Sugarbaker pioneered—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your [[Asbestos Exposure\|asbestos exposure]].<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

	The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.		The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.
Line 246:		Line 246:
	* [[History_of_Mesothelioma_Research\|History of Mesothelioma Research]]		* [[History_of_Mesothelioma_Research\|History of Mesothelioma Research]]
	* [[Dr_Raphael_Bueno\|Dr. Raphael Bueno]] (Successor at IMP)		* [[Dr_Raphael_Bueno\|Dr. Raphael Bueno]] (Successor at IMP)
	* [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] (Peritoneal Mesothelioma Pioneer)		* [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] ([[Peritoneal Mesothelioma]] Pioneer)
	* [[Dr_Robert_Cameron\|Dr. Robert Cameron]]		* [[Dr_Robert_Cameron\|Dr. Robert Cameron]]
	* [[Dr_Paul_Baas\|Dr. Paul Baas]]		* [[Dr_Paul_Baas\|Dr. Paul Baas]]

← Older revision		Revision as of 14:28, 29 January 2026
Line 7:		Line 7:
	\|published_time=2026-01-28		\|published_time=2026-01-28
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276~~; background:#ffffff; color:#333333~~; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. David J. Sugarbaker, MD		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. David J. Sugarbaker, MD
	\|-		\|-
	\| colspan="2" style="~~background:#e8f4f8; color:#333333;~~ padding:10px; text-align:center; font-style:italic;" \| Architect of Trimodal Therapy		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Architect of Trimodal Therapy
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Born		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| Born
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 6, 1949		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 6, 1949
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Died		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Died
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 29, 2018 (age 69)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 29, 2018 (age 69)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Institution		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Institution
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Brigham and Women's Hospital		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Brigham and Women's Hospital
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Key Innovation		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Key Innovation
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Trimodal Therapy		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Trimodal Therapy
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~; border-bottom:1px solid #dee2e6;" \| Program Founded		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Program Founded
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International Mesothelioma Program (2002)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International Mesothelioma Program (2002)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa; color:#333333~~;" \| Survival Achievement		\| style="padding:10px; font-weight:bold; " \| Survival Achievement
	\| style="padding:10px;" \| 35.6 months median		\| style="padding:10px;" \| 35.6 months median
	\|-		\|-
Line 48:		Line 48:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. David Sugarbaker's Contributions		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. David Sugarbaker's Contributions
	\|-		\|-
	\| style="padding:15px~~; background:#f8f9fa; color:#333333~~;" \|		\| style="padding:15px; " \|
	* '''Surgical Innovation:''' Pioneered extrapleural pneumonectomy (EPP) for mesothelioma		* '''Surgical Innovation:''' Pioneered extrapleural pneumonectomy (EPP) for mesothelioma
	* '''Trimodal Therapy:''' Developed approach combining surgery + chemotherapy + radiation		* '''Trimodal Therapy:''' Developed approach combining surgery + chemotherapy + radiation
Line 67:		Line 67:
	His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER Program</ref>		His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER Program</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."
Line 106:		Line 106:
	\|}		\|}

	{\| style="width:100%~~; background:#fff3cd~~; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#856404~~;" \| '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.		\| style="padding:15px; " \| '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.
	\|}		\|}

Line 142:		Line 142:
	In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.6 months, with half of patients living even longer.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>		In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.6 months, with half of patients living even longer.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hipec HIPEC Definition], NCI Dictionary of Cancer Terms</ref>

	{\| style="width:100%~~; background:#d4edda~~; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#155724~~;" \| '''✅ Survival Achievement:''' Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.6 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.		\| style="padding:15px; " \| '''✅ Survival Achievement:''' Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.6 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.
	\|}		\|}

Line 163:		Line 163:
	This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>		This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."
Line 227:		Line 227:
	* '''Research Infrastructure:''' Tissue banks and databases support ongoing research		* '''Research Infrastructure:''' Tissue banks and databases support ongoing research

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa; color:#333333~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."